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In Brief Wang et al. identify angiogenin (ANG) as a ligand for epidermal growth factor receptor (EGFR). ANG-mediated EGFR activation can trigger oncogenic transformation, and high ANG in the plasma of pancreatic adenocarcinoma patients positively correlates with response to the EGFR inhibitor erlotinib.
INTRODUCTION
Epidermal growth factor receptor (EGFR) is an effective target for anticancer therapies in certain clinical settings (Avraham and Yarden, 2011; Lee et al., 2015) . Notably, EGFR tyrosine kinase inhibitors (TKIs) have been approved to treat both lung and pancreatic cancers (Moore et al., 2007; Shepherd et al., 2005) .
EGFR-activating mutations identified in lung cancers have been well demonstrated to predict response to EGFR-TKI. Moreover, EGFR-mutated lung cancers are often addicted to EGFR activation and sensitive to EGFR-TKI, resulting in prolonged lifespan of a number of lung cancer patients (Rosell et al., 2012) . However, those mutations are infrequent in PDAC (Tzeng et al., 2007; Wang et al., 2015) , and EGFR-TKI erlotinib has shown Significance EGFR ligand ANG serves as a serum biomarker to predict response to erlotinib, an EGFR tyrosine kinase inhibitor, in PDAC. Knockdown of ANG demonstrates its oncogenic role and decreases sensitivity to erlotinib treatment in vitro and in vivo. High plasma ANG level in patients is positively associated with their response to erlotinib treatment in a small patient cohort, highlighting the interplay between ANG and EGFR in PDAC. This oncogene addiction effect may be advantageous for the development of a serum biomarker-guided target therapy in malignancies. The ANG-EGFR axis also opens an avenue toward our understanding of the ligand-receptor cognate signaling between RNases and RTKs, bridging two unrelated protein families via this ligand function of RNases.
